Day 90 NGS-Based MRD Negativity Predicts Survival after BCMA-Directed CAR T-cell Therapy for Relapsed or Refractory Multiple Myeloma.

Transplantation and Cellular Therapy 2026

View at publisher
Authors: Brandon J Kale, David Kaldas, Lucas Lee, Brandon Jamaal Blue, Ariel Felipe Grajales-Cruz, Gabriel De Avila, David Scheiber-Camoretti, Ariosto Silva, Danny DeAvila, Kristy Matte, Laura B Oswald, Lauren Cole Peres
+11 more Rebecca M. Gonzalez, Hien Liu, Kenneth H Shain, Rachid C Baz, Taiga Nishihori, Melissa Alsina, Ciara L Freeman, Frederick L Locke, Fabiana Perna, Omar Castañeda Puglianini, Doris K. Hansen
DOI: 10.1016/j.jtct.2025.12.597
Cited by: 1

Fields of Study & Subjects

CAR-T cell therapy research Multiple Myeloma Research and Treatments Chronic Lymphocytic Leukemia Research

Publication details

Journal / source
Transplantation and Cellular Therapy
Publisher
Elsevier BV
Volume
32
Issue
2
Pages
S416–S416
Publication date
1 February 2026
Language
EN